PitchSend

Investor Presentaiton

sanofi SP0256 Phase 1/2 trial design of mono vaccine in older adults Days 29 mRNA Dose 1 ; LNP #1 mRNA Dose 1 ; LNP #2 n= 10 & 100 > Safety n= 10 & 100 Adults 18-49 mRNA Dose 2 ; LNP #1 n= 10 & 100 mRNA Dose 2 ; LNP #2 n= 10 & 100 & ≥60 yo mRNA Dose 3 ; LNP #1 n= 10 & 100 Adverse events following vaccination > Immunogenicity Serum neutralizing antibody response measured by plaque reduction neutralization assay mRNA Dose 3 ; LNP #2 n= 10 & 100 Placebo n= 10 & 100 37 Vaccines Investor Event

View entire presentation